HIV-Associated Pneumocystis Pneumonia Outcomes
Author Information
Author(s): Radhi Saba, Alexander Travis, Ukwu Michelle, Saleh Samer, Morris Alison
Primary Institution: University of Southern California
Hypothesis
What is the epidemiology of Pneumocystis pneumonia (PCP) in HIV-infected patients and how does highly active antiretroviral therapy (HAART) impact PCP outcomes?
Conclusion
In-hospital mortality for HIV-infected patients with PCP is similar to earlier reports, and HAART use did not significantly affect mortality.
Supporting Evidence
- Overall hospital mortality was 11.6%.
- Mortality in patients requiring intensive care was 29.0%.
- The need for mechanical ventilation, development of a pneumothorax, and low serum albumin were independent predictors of increased mortality.
- HAART use before or during hospitalization was not associated with mortality.
Takeaway
This study looked at patients with a lung infection related to HIV and found that many still get sick even if they are on treatment, and the treatment doesn't seem to help them get better in the hospital.
Methodology
A retrospective cohort study of 262 patients diagnosed with PCP between January 2000 and December 2003, analyzing hospital mortality and predictors of mortality.
Potential Biases
Potential bias in treatment decisions and patient selection for HAART.
Limitations
The study is retrospective and from a single center, which may limit generalizability.
Participant Demographics
Median age was 40 years, 84.2% were male, and 51.7% were Hispanic/Latino.
Statistical Information
P-Value
0.52
Confidence Interval
95%CI [1.60–4.30]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website